A budget impact model for biosimilar infliximab in Crohns disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

V. Brodszky, F. Rencz, M. Péntek, P. Baji, P.L. Lakatos, L. Gulácsi

Research output: Contribution to journalArticle (Academic Journal)peer-review

58 Citations (Scopus)
Original languageEnglish
JournalExpert review of pharmacoeconomics and outcomes research
Early online date10 Jul 2015
Publication statusPublished - 2016

Cite this